Please login to the form below

Not currently logged in
Email:
Password:

Arresto Biosciences

This page shows the latest Arresto Biosciences news and features for those working in and with pharma, biotech and healthcare.

Gilead chalks up trial success for new NASH drug

Gilead chalks up trial success for new NASH drug

The phase II trial is looking at selonsertib (GS-4997) on its own or in combination with Gilead's other NASH candidate simtuzumab - acquired along with Arresto Biosciences for $225m in

Latest news

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    The antibody - which was acquired by Gilead when it bought Arresto Biosciences for $225m in 2010 - has previously failed to show efficacy in a pancreatic cancer trial.

  • Gilead's simtuzumab fails pancreatic cancer trial Gilead's simtuzumab fails pancreatic cancer trial

    Simtuzumab - which was acquired by Gilead when it bought Arresto Biosciences for $225m in 2010 - is also in phase II trials for idiopathic pulmonary fibrosis, myelofibrosis, non-alcoholic steatohepatitis (NASH) and

  • Gilead to acquire Calistoga

    The Calistoga acquisition comes on the heels of the company's acquisitions last year of two other small biotech companies, CGI Pharmaceuticals and Arresto Biosciences, both of which are also developing ... Gilead acquired Arresto for $225m plus potential

  • Gilead to acquire Arresto Bioscences

    Gilead will acquire Arresto Biosciences for $225m plus potential future payments based on sales levels. ... Arresto Viosciences is a privately held development-stage technology company focused on medicines to treat fibrotic diseases and cancer.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics